As a result, starch‐rich diets could lead to elevated blood levels of 1,5‐AG, which might explain why patients with GSDIb tend to have higher baseline 1,5‐AG levels and respond less effectively to SGLT2 inhibitor therapy compared to those with G6PC3 deficiency, making the neutropenia in GSDIb patients more challenging to treat. The gene discussed is SLC5A2; the disease is neutropenia.